NR4A1 and breast carcinoma: Antiestrogen therapy with agents such as tamoxifen (TAM) and aromatase inhibitors is the cornerstone of systemic breast cancer therapy, which has significantly improved the survival of women with hormone receptor-positive (HR) breast cancers [2–4].